Literature DB >> 2716426

[Prevalence of hepatitis B infection in institutions for the mentally retarded. Epidemiologic characteristics in the province of Vizcaya].

J Aristegui Fernández, R Cisterna Cáncer, J Muñiz Saitua, E Gorostiza, A Pérez Legorburu, B Cos Arregui, A Delgado Rubio.   

Abstract

The prevalence of hepatitis B virus (HBV) infection was studied in 346 subjects (148 employees and 198 mentally retarded) in four institutions for the mentally subnormal in Vizcaya-Spain. The prevalence of markers in the overall group was 32.6%; 13.5% in the employees and 46.9% in the mentally retarded. Early age and institutionalization time increases the risk of infection in the mentally retarded group, but not in the employees group. 220 subjects (118 employees and 102 mentally retarded) had negative HBV markers and were vaccinated with recombinant-DNA hepatitis B vaccine. The immunogenicity was 80% and the weight-height index the only factor implicit in the group of subjects no seroconverters. The reactogenicity of vaccine was 6.7%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2716426

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  4 in total

Review 1.  The emerging role of the client in the delivery of primary care to older Americans.

Authors:  M A Counte
Journal:  Health Serv Res       Date:  1998-06       Impact factor: 3.402

2.  Prevalence of hepatitis B infection in long-stay mentally handicapped adults.

Authors:  F Asensio; J M Bayas; M J Bertran; M A Asenjo
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

3.  Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection in Spanish leprosy patients.

Authors:  A González Quintela; M Moya; I Millán; C Marín
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

4.  Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

Authors: 
Journal:  BMJ       Date:  1991-10-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.